Author: Editor

Lee S. Schwartzberg, MD of University of Tennessee Health Science Center explains which patients should get endocrine therapy and genomic profiling in breast cancer. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Lee S. Schwartzberg, MD of University of Tennessee Health Science Center explains the use of genomic profiling for prognoses in breast cancer, which shows the chances of relapse and a prediction for endocrine therapy or chemotherapy. He states that with genomic profiling, oncologists can tailor their treatments based on these results. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Lee S. Schwartzberg, MD of University of Tennessee Health Science Center discusses the treatment trends in 2017 for estrogen receptor positive breast cancer, which include the use of CDK46 inhibitors. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Lee S. Schwartzberg, MD of University of Tennessee Health Science Center discusses current clinical trials and genomic profiling in breast cancer research. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Shaji K. Kumar, MD of Mayo Clinic

Shaji K. Kumar, MD of Mayo Clinic gives an overview of the upcoming treatment trends for multiple myeloma, which include combination therapy after relapse, longer duration of treatment, early intervention, and clinical trials development. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Shaji K. Kumar, MD of Mayo Clinic discusses how to gain a better understanding in treating multiple myeloma. He states that most patients who are treated end up relapsing, so oncologists need to figure out why they continue to relapse and how does the disease evolve over time. Ultimately, oncologists need to concentrate more on the biology of the disease to better treat patients. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Shaji K. Kumar, MD of Mayo Clinic CHANGE TITLE–Myeloma

Matthew H. Kulke, MD, MMSc of Dana-Farber and Harvard Medical School explains whether or not somatostatin analogues were needed to see efficacy in treatment for carcinoid syndromes. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Matthew H. Kulke, MD, MMSc of Dana-Farber and Harvard Medical School gives an overview of his discussion, Novel Treatment Options for Neuroendocrine Tumors, which was presented at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Matthew H. Kulke, MD, MMSc of Dana-Farber and Harvard Medical School discusses the results of the NETTER-1 study, which concluded with patients who were treated with octreotide had significantly improved progression free survival compared to patients who were not treated with the drug. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Kilian E. Salerno, MD of Roswell Park Cancer Institute? explains what to do with patients who have neo-adjuvant chemotherapy and how the response to chemotherapy affects the radiation oncologist’s decision on what should be treated or not. She states that based on the guidelines, the role of radiation is defined by the maximal disease stage. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Kilian E. Salerno, MD of Roswell Park Cancer Institute? stresses the importance of tailoring treatment options to patients’ specific risks. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Kilian E. Salerno, MD of Roswell Park Cancer Institute? discusses the role for regional nodal irradiation in breast cancer treatment. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Kilian E. Salerno, MD of Roswell Park Cancer Institute? gives an overview of the new radiation guidelines for treating patients with breast cancer. She states there are several evolving treatment options and to communicate with patients which options work best for them. She stresses the importance of tailoring those treatment options to the patients’ individual needs and desires. 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Kilian E. Salerno, MD of Roswell Park Cancer Institute? explains how to select effective radiation options for breast cancer treatment. She argues that more treatment is only better if it benefits the patient in the long-run, and ultimately, she is learning that sometimes, more is not always better in select patients. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Kilian E. Salerno, MD of Roswell Park Cancer Institute? gives an overview of her presentation, “Evolving Radiation Therapy Recommendations for Breast Cancer,” which was presented at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Kilian E. Salerno, MD of Roswell Park Cancer Institute? discusses treatment trends in 2017 for breast cancer treatment. She states that many parts of breast cancer management is gravitating towards less radiation and how to use neo-adjuvant chemotherapy to assess next treatments. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Clifford Goodman, PhD of Lewin Group gives an overview of the types of evidence that the National Comprehensive Cancer Network (NCCN) look for when it comes to their guidelines. He states that the NCCN panel is looking for data from not only clinical trials, but other complementary sources of data. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Clifford Goodman, PhD of Lewin Group discusses concerns over patient affordability with cancer care. He argues that the separation between the level of quality in cancer care and what the patient can afford is widening. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Clifford Goodman, PhD of Lewin Group gives an overview of another theme from his session, which was disparities in cancer care. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Clifford Goodman, PhD of Lewin Group gives an overview of the National Comprehensive Cancer Network’s (NCCN) guidelines program and the addition of the evidence blocks. He states that the evidence blocks have an element of affordability, which provides an opportunity for oncologists and other health care professionals to talk with patients about costs. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Clifford Goodman, PhD of Lewin Group discusses themes of his session, which included concerns over cutbacks for the National Institute of Health (NIH). He states that we need continuity in funding of cancer research. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Clifford Goodman, PhD of Lewin Group discusses concerns about a rollback in coverage, losses in preventive services, and affordability in cancer care, which were covered at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Stephen B. Edge, MD of Roswell Park Cancer Institute gives an overview of the new staging system by the American Joint Committee on Cancer (AJCC). This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Stephen B. Edge, MD of Roswell Park Cancer Institute discusses questions he received from the audience, one being whether or not the staging system is becoming too complicated. He answers yes, it is getting more complicated and more confusing, but at the same time, this will overall improve the value of staging. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Stephen B. Edge, MD of Roswell Park Cancer Institute gives an overview of his presentation “Implications of the New AJCC Staging System,” which was presented at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Stephen B. Edge, MD of Roswell Park Cancer Institute explains how health care disparities have become a critical issue and an area of discussion at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Stephen B. Edge, MD of Roswell Park Cancer Institute discusses the importance of personalized medicine, specifically genomic profiling in breast cancer. He states that with more use in genomic profiling, chemotherapy has decreased in need. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Stephen B. Edge, MD of Roswell Park Cancer Institute discusses the American Joint Committee on Cancer (AJCC) and its collaboration with Union International Cancer Control (UICC) for global use, where patients can be compared across the globe. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Lois Ramondetta, MD of MD Anderson Cancer Center gives an overview of her presentation, HPV Vaccine Champion Training for Gynecologic Oncologists, which was presented with Dr. Jennifer Young Pierce of Medical University of South Carolina at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Lois Ramondetta, MD of MD Anderson Cancer Center discusses the importance of communicating the safety and efficacy of the HPV vaccine with other healthcare professionals, primary care physicians, and families. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Lois Ramondetta, MD of MD Anderson Cancer Center gives an overview of an HPV-related abstract that was discussed at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD. She states that the abstract argued the importance of the vaccine in preventing around 6 different types of cancer (vaginal, penile, vulvar, cervical, anal, oropharyngeal).

Jennifer Young Pierce, MD of Medical University of South Carolina gives an overview of her presentation, HPV Vaccine Champion Training for Gynecologic Oncologists, which was presented with Dr. Lois Ramondetta of MD Anderson Cancer Center at the Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Jennifer Young Pierce, MD of Medical University of South Carolina gives an overview of the practical guidelines for gynecologic oncologists in getting involved with the HPV vaccine outreach. She lists talking with physicians about the vaccine’s role in cancer prevention, introducing survivors, and working with local cancer facilities as just a few approaches. This was recorded at the Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Jennifer Young Pierce, MD of Medical University of South Carolina discusses the importance of spreading HPV vaccine awareness, especially the data that shows the impact of the vaccine in cancer prevention. This was recorded at the Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Jennifer Young Pierce, MD of Medical University of South Carolina gives an overview of the treatment trends for the HPV vaccine in 2017. One specific treatment trend is to go from a 3 dose regiment to a 2 dose for regiment for the vaccine, which allows increase completion rates since it can be difficult for patients to come back for the third dose. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Elizabeth Swisher, MD of University of Washington Medical Center discusses the treatment trends for ovarian cancer for 2017. She highlights the use of FDA-approved PARP inhibitors, immunotherapy, and even combination therapy with PARP inhibitors and immunotherapy. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Elizabeth Swisher, MD of University of Washington Medical Center explains why it is crucial to use both germline and tumor testing instead of completely skipping germline testing. She states that if clinicians skip the initial germline testing, 10% of BRCA 1 mutations will be missed. This was recorded at the Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Elizabeth Swisher, MD of University of Washington Medical Center discusses development of more efficient clinical tests that will accurately predict which patients respond to PARP inhibitors. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Elizabeth Swisher, MD of University of Washington Medical Center gives an overview of a second presentation that discussed the ARIEL2 Trial at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD. From the presentation, the data concluded that the patients who developed platinum-resistance were less likely to respond to the drug. She argues clinicians need to introduce the drug earlier in treatment so patients don’t develop resistance.

Elizabeth Swisher, MD of University of Washington Medical Center discusses her hopes in the ARIEL2 Trial in helping to optimize predictor of response for patients with not only ovarian cancer, but other cancers as well. She states that ovarian cancer is the leading factor in the field of PARP inhibitors and what is learned in ovarian cancer can be applicable to other cancers. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Ruben A. Mesa, MD of Mayo Clinic discusses questions from the audience that were asked during his session on the new guidelines for myeloproliferative neoplasms. He states that overall quality has become the main focus for these guidelines. This was recorded at 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Ruben A. Mesa, MD of Mayo Clinic gives an overview of the upcoming treatment trends for myeloproliferative neoplasms, which include new FDA approved agents, JAK inhibitors, and combination studies. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Ruben A. Mesa, MD of Mayo Clinic gives an overview of interesting topics, such as health disparities and access to care, which were discussed at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Ruben A. Mesa, MD of Mayo Clinic explains the importance of the NCCN and its development of new guidelines for cancer care. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Ruben A. Mesa, MD of Mayo Clinic gives an overview of the new guidelines that are set for leukemia. He states that guidelines ultimately help to identify key areas of unmet needs, specifically drivers in the spectrum of chronic leukemia toward acute leukemia. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Saketh Guntupalli, MD of University of Colorado School of Medicine gives an overview of the kinds of treatment trends for 2017 in his specialty. He states that as a clinician and a surgeon, he hopes to improve the quality of surgeries by finding an easier way to prevent complications, such as blood clots, from happening. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Saketh Guntupalli, MD of University of Colorado School of Medicine explains how patients were picked for his clinical study and their responses to the trial. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Saketh Guntupalli, MD of University of Colorado School of Medicine discusses the importance of his study and how he hopes that the increase of compliance with medication can help prevent blood clots and other bleeding risks in the future. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.